These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27159396)

  • 1. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.
    Lock R; Ingraham R; Maertens O; Miller AL; Weledji N; Legius E; Konicek BM; Yan SC; Graff JR; Cichowski K
    J Clin Invest; 2016 Jun; 126(6):2181-90. PubMed ID: 27159396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
    Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG
    Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs.
    Grit JL; McGee LE; Tovar EA; Essenburg CJ; Wolfrum E; Beddows I; Williams K; Sheridan RTC; Schipper JL; Adams M; Arumugam M; Vander Woude T; Gurunathan S; Field JM; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
    Oncogene; 2024 May; 43(19):1411-1430. PubMed ID: 38480916
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Giraud JS; Bièche I; Pasmant É; Tlemsani C
    Expert Opin Investig Drugs; 2023; 32(10):941-957. PubMed ID: 37747491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
    de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
    J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MNK Inhibition Sensitizes
    Knight JRP; Alexandrou C; Skalka GL; Vlahov N; Pennel K; Officer L; Teodosio A; Kanellos G; Gay DM; May-Wilson S; Smith EM; Najumudeen AK; Gilroy K; Ridgway RA; Flanagan DJ; Smith RCL; McDonald L; MacKay C; Cheasty A; McArthur K; Stanway E; Leach JD; Jackstadt R; Waldron JA; Campbell AD; Vlachogiannis G; Valeri N; Haigis KM; Sonenberg N; Proud CG; Jones NP; Swarbrick ME; McKinnon HJ; Faller WJ; Le Quesne J; Edwards J; Willis AE; Bushell M; Sansom OJ
    Cancer Discov; 2021 May; 11(5):1228-1247. PubMed ID: 33328217
    [No Abstract]   [Full Text] [Related]  

  • 7. Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functional Nf1 to apoptosis in the absence of protein kinase C.
    Ganapathy S; Fagman JB; Shen L; Yu T; Zhou X; Dai W; Makriyannis A; Chen C
    Oncotarget; 2016 Dec; 7(51):84326-84337. PubMed ID: 27741517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival.
    Black LE; Longo JF; Anderson JC; Carroll SL
    Am J Pathol; 2023 Sep; 193(9):1298-1318. PubMed ID: 37328102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.
    Malone CF; Emerson C; Ingraham R; Barbosa W; Guerra S; Yoon H; Liu LL; Michor F; Haigis M; Macleod KF; Maertens O; Cichowski K
    Cancer Discov; 2017 Dec; 7(12):1450-1463. PubMed ID: 28963352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.
    De Raedt T; Beert E; Pasmant E; Luscan A; Brems H; Ortonne N; Helin K; Hornick JL; Mautner V; Kehrer-Sawatzki H; Clapp W; Bradner J; Vidaud M; Upadhyaya M; Legius E; Cichowski K
    Nature; 2014 Oct; 514(7521):247-51. PubMed ID: 25119042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofibromin 1 controls metabolic balance and Notch-dependent quiescence of murine juvenile myogenic progenitors.
    Wei X; Rigopoulos A; Lienhard M; Pöhle-Kronawitter S; Kotsaris G; Franke J; Berndt N; Mejedo JO; Wu H; Börno S; Timmermann B; Murgai A; Glauben R; Stricker S
    Nat Commun; 2024 Feb; 15(1):1393. PubMed ID: 38360927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin shares common mTOR and MAPK signaling mechanisms with other lifespan extension treatments.
    Jiang E; Dinesh A; Jadhav S; Miller RA; Garcia GG
    Life Sci; 2023 Sep; 328():121904. PubMed ID: 37406767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective and effective suppression of pancreatic cancer through MNK inhibition.
    Li H; Yao Y; Hao R; Long C
    Immunopharmacol Immunotoxicol; 2024 Aug; ():1-11. PubMed ID: 39138614
    [No Abstract]   [Full Text] [Related]  

  • 14. Past, Present, and Future Therapeutic Strategies for NF-1-Associated Tumors.
    Na B; Shah SR; Vasudevan HN
    Curr Oncol Rep; 2024 Jun; 26(6):706-713. PubMed ID: 38709422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-Target In Silico Prediction of Inhibitors for Mitogen-Activated Protein Kinase-Interacting Kinases.
    Halder AK; Cordeiro MNDS
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of MNK-PROTACs.
    Sun X; Wu Q; Bu H; Pei Y; Guan D; Guo S; Zhou J; Zhang H
    Mol Divers; 2024 Mar; ():. PubMed ID: 38498082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.
    Allaway RJ; Wood MD; Downey SL; Bouley SJ; Traphagen NA; Wells JD; Batra J; Melancon SN; Ringelberg C; Seibel W; Ratner N; Sanchez Y
    Oncotarget; 2018 Mar; 9(22):15860-15875. PubMed ID: 29662612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal circadian oscillation of hippocampal MAPK activity and power spectrums in NF1 mutant mice.
    Chen L; Serdyuk T; Yang B; Wang S; Chen S; Chu X; Zhang X; Song J; Bao H; Zhou C; Wang X; Dong S; Song L; Chen F; He G; He L; Zhou Y; Li W
    Mol Brain; 2017 Jul; 10(1):29. PubMed ID: 28673309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.
    Trousil S; Chen S; Mu C; Shaw FM; Yao Z; Ran Y; Shakuntala T; Merghoub T; Manstein D; Rosen N; Cantley LC; Zippin JH; Zheng B
    J Invest Dermatol; 2017 May; 137(5):1135-1143. PubMed ID: 28143781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Imidazo[2,1-
    Jin X; Qiu T; Xie J; Wei X; Wang X; Yu R; Proud C; Jiang T
    ACS Med Chem Lett; 2023 Jan; 14(1):83-91. PubMed ID: 36655132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.